IL18 and cancer: These data suggest that DBMSCs may enhance the anticancer activities of NK cells through their receptors IL-18 and IFNγ, which normally mediate the stimulatory effects of NK cells on cancer cells (Hafner et al., 1999; Wong et al., 2013; Mandai et al., 2016) as previously reported for DPMSCs and pMSCs (Abumaree et al., 2018; 2019b).